Desjardins Global Asset Management’s BeOne Medicines Ltd ONC Stock Holding History

Desjardins Global Asset Management’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,726	Closed	-$308K	–	726
2023 Q2	$308K	Buy	1,726 +334	+24%	+$76.9K	0.04%	378
2023 Q1	$300K	Sell	1,392 -253	-15%	-$60.7K	0.04%	354
2022 Q4	$361K	Buy	1,645 +211	+15%	+$38.7K	0.06%	268
2022 Q3	$193K	Sell	1,434 -89	-6%	-$15.3K	0.02%	345
2022 Q2	$246K	Buy	1,523 +107	+8%	+$16.7K	0.03%	325
2022 Q1	$267K	Sell	1,416 -34	-2%	-$7.23K	0.02%	335
2021 Q4	$392K	Buy	+1,450	New	+$490K	0.03%	300

Other funds holding ONC

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

CII

Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return

Desjardins Global Asset Management's ONC Position: Q3 2023 in Review

Desjardins Global Asset Management sold out of BeOne Medicines Ltd (ONC) in Q3 2023, closing a stake of 1,726 shares — an estimated $308K sold.

Desjardins Global Asset Management first reported a position in ONC in Q4 2021 and held it in 7 quarters. The position peaked at $392K in Q4 2021. 200 funds tracked by Wall St. Rank hold ONC as of Q3 2023.

Desjardins Global Asset Management reported no remaining BeOne Medicines Ltd position as of Q3 2023 after selling out during the quarter.
Desjardins Global Asset Management sold 1,726 BeOne Medicines Ltd shares in Q3 2023, an estimated $308K.
Desjardins Global Asset Management first reported a position in BeOne Medicines Ltd in Q4 2021 and held it in 7 quarters.
Desjardins Global Asset Management's BeOne Medicines Ltd position peaked at $392K in Q4 2021.
200 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q3 2023.

Based on Desjardins Global Asset Management's 13F filing for Q3 2023, filed 8 Nov 2023.